Sun Pharmaceutical Industries today said one of its wholly owned subsidiaries has launched generic metformin hydrochloride extended release tablets, used for glycemic control, in the US market.
The tablets have been launched in the strengths of 500 mg and 1000 mg, it said in a filing to BSE.
The tablets are generic versions of Santarus Inc's Glumetza HCl extended release tablets in the same strengths, it added.
"The addressable market size is approximately USD 443 million for the 12 months ending April 2018, as per IQVIA," Sun Pharma said.
The tablets are used to improve glycemic control in adults with type 2 diabetes.
The Sun Pharma stock was trading 0.24 per cent down at Rs 561.15 in the afternoon on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app